This is a renewal application for a multi-disciplinary hematology training program at the New York University School of Medicine. The program is designed to provide two-year research opportunities for 5 post-doctoral fellows under the guidance of a faculty of 13 mentors. The formal teaching activities include a core curriculum hematology course, weekly seminars and the availability of courses in molecular biology, immunology and statistics. The training faculty consists of academic hematologists with active laboratories applying basic science methods to the study of hematologic disorders as well as mentors of the basic science departments of NYU Medical Center. The training faculty consists of academic hematologists with active laboratories applying basic science methods to the study of hematologic disorders as well as mentors of the basic science departments of NYU Medical Center. There is abundant interaction among the faculty members within the program as well as with other scientists at this institution and elsewhere. The clinical research at this institution has been recognized by the NIH and its designation as a Comprehensive Cancer Center and an AIDS Center. The program director's research spans both areas. New faculty members have strengthened the basic science orientation of the program. The faculty works within this framework to train physician-scientists for future work in the academic community. The proposed research areas span basic science (cell proliferation, signal transduction, homeobox genes) in the laboratories of Drs Schlessinger, Basilico, Ziff and Takeshita, to direct clinical relevance (angiogenesis, hematopoiesis, thrombopoiesis, retinoic acid receptors, antigen-immuno regulation, lymphomas, chronic lymphocytic leukemia, Kaposi's sarcoma, amyloidosis, thrombosis in the newborn and thrombosis in cancer) in the laboratories of Drs. Green, Basch, Zucker-Franklin, Takeshita, Thorbecke, Inghirami, Jacobson, Huang, M. Karpatkin and S. Karpatkin. A current theme of all the projects is their orientation to human disease.
These aims will be accomplished by training promising candidates in the design. execution and evaluation of experiments yielding results that will be offered to peer-reviewed journals. Eventually, the trainees will take their place in future ranks of academic medicine using the approached learned during their stay with our faculty.
Saint Fleur-Lominy, Shella; Maus, Mate; Vaeth, Martin et al. (2018) STIM1 and STIM2 Mediate Cancer-Induced Inflammation in T Cell Acute Lymphoblastic Leukemia. Cell Rep 24:3045-3060.e5 |
Cullis, Jane; Siolas, Despina; Avanzi, Antonina et al. (2017) Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer. Cancer Immunol Res 5:182-190 |
Sayin, Volkan I; LeBoeuf, Sarah E; Singh, Simranjit X et al. (2017) Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer. Elife 6: |
Fehrenbacher, Nicole; Tojal da Silva, Israel; Ramirez, Craig et al. (2017) The G protein-coupled receptor GPR31 promotes membrane association of KRAS. J Cell Biol 216:2329-2338 |
Strazza, Marianne; Azoulay-Alfaguter, Inbar; Peled, Michael et al. (2017) PLC?1 regulates SDF-1?-induced lymphocyte adhesion and migration to sites of inflammation. Proc Natl Acad Sci U S A 114:2693-2698 |
Pyzer, A R; Stroopinsky, D; Rosenblatt, J et al. (2017) MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs. Leukemia 31:2780-2790 |
Romero, Rodrigo; Sayin, Volkan I; Davidson, Shawn M et al. (2017) Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat Med 23:1362-1368 |
Bar-Natan, Michal; Stroopinsky, Dina; Luptakova, Katarina et al. (2017) Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. Br J Haematol 176:929-938 |
Xiang, Michael; Kim, Haesook; Ho, Vincent T et al. (2016) Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood 128:1845-1853 |
Santori, Fabio R (2015) The immune system as a self-centered network of lymphocytes. Immunol Lett 166:109-16 |
Showing the most recent 10 out of 45 publications